Lupus

Can We Predict Work Disability in Lupus? When it comes to managing patients with SLE there are many aspects of the disease to consider – disease activity, organs involved, and the potential for long term damage. Given that SLE affects many working-age adults, there is another https://t.co/9Fp4MxKpw9

@RheumNow Determinates of health and outcomes in Rheumatic diseases #2. Lupus nephritis & race: Evidence to support racial/ethnic differences in Rx efficacy is limited. ACR 2024 guidelines do NOT recommend basing treatment decisions on race or ethnicity. #ACR26

Dazodalibep (CD40/CD40L inhibitor) for Sjogren's Improved ESSDAI at both doses compared to PBO Q4 week dosing w/ improvements in dryness Sig. improvement but PBO also did fairly well... how much is an ESSDAI delta of -1.4 to -1.8 clinically meaningful... @RheumNow #ACR26 LB22 https://t.co/AEBtjpJq1F

https://x.com/Dr_Brian_MD/status/2120533479813161024/photo/1

Article

CAR T Gets the Spotlight. Are We Missing the B Cells That Matter?

Melissa Akselrad, MD Nov 11, 2026

CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies we already have?

#Sjogren’s is no longer a #dry #Rx landscape Which to choose in future? #Ianalumab #dazodalibep DIff #MOA #CD40L #CD20 deleted+ altered B cell Signalling +RCTs of each Can’t compare between drugs #efficacy 🤷 #ACR2026 @RheumNow @ACRheum #LB22 #1861 shows #Iana effects https://t.co/73D0ENtcnZ

#FcRn #efigartigimod + #RCT in #IMNM & #DM #LB24 But 😞 #SjD RCT stopped 🛑 for #futility We will have niche Rx for many rare #SARDs I think over next few yrs #ACR26 @ACRheum @RheumNow

ALKIVIA trial: Ph3 RCT of Efgargitimod (EFG) SC for IIM Met primary endpt of achieving TIS vs PBO in IMNM+DM w/ early improvement observed by wk 4 Primary key secondary endpts also met Infection rates similar bet EFG & PBO 1st successful trial in IMNM @RheumNow #ACR26 LB24 https://t.co/Az9cH5Fyhh

Ph2 RCT of Afimetoran (TLR7/8) for SLE: Met primary endpt of SRI-4 for all 3 doses at wk 48 (p<0.001); >30% vs PBO IFN gene suppression as early as wk 24 Afi incr C3/C4, antidsDNA over time Well-tolerated, SAEs comp across all 3 arms, no new safety signals @RheumNow #ACR26 LB23 https://t.co/gBrd7gpOkJ

Primary SRI-4 in active #SLE met W TLR7/8 #AFIMETORAN Wow! RCT is ☑️ Less infections and great high bar outcomes #ACRbest #LB23 @RheumNow @ACRheum https://t.co/cvcWVlBRmC https://t.co/CaRdcR8VWw

NEW #MOA in #SLE TLR7/8 #Afimetoran Drives Interferon T1 TLR7 Changes organ damage TLR8 1 or more background #lupus #Rx mandated #prednisone taper Aim <7.5mg/d #GCs Mean #SLEDAI 8, CLASI 7-8 Mean pred 9.5-10.5 85%HCQ #ACR26 @RheumNow @ACRheum #LB24 https://t.co/EXCnYdc7O3

LB23: Ph2 trial Afimetoran (TLR7/8 inhibitor) in pts w active SLE - all 3 doses higher SRI-4 response v PBO: 64.1%-67.8% vs 34.4% - secondary measures c/w with SRI-4 (BICLA, LLDAS, GC sparing, & others) - infection most common reported AE @RheumNow #ACR26 https://t.co/5WGDCHygcP

https://x.com/AkhilSoodMD/status/2120520168883544262/photo/1

OASIZ-301 Trial- Dazodalibep for SjD Both DAZ arms (3000mg & 1500mg) demonstrated sign. improvements in ESSDAI at wk 48 vs PBO DAZ arms also met key sec endpts - including sign. improved ESSPRI/DASPRI dryness domains w/1500mg Both arms safe & welltolerated @RheumNow #ACR26 LB22 https://t.co/GjnDCWkMG7

Kalunian et al. Phase 2 RCT of Afimetoran, oral TLR 7/8i in SLE. 248 patients. Met SRI-4 in all groups. No dose dependent effect. Less serious adverse events with afimetoran vs placebo. @RheumNow #ACR26 Abstr#LB23 https://t.co/jlTO5OeD2N

https://x.com/RichardPAConway/status/2120518407129096629/photo/1

Noaiseh et al. Phase 3 OASIZ-301 RCT. Dazodalibep in Sjogens. Positive study. Effect by week 4. Secondary outcomes on sicca also met. Similar adverse events to placebo. @RheumNow #ACR26 Abstr#LB22 https://t.co/s4E44IMpS8

https://x.com/RichardPAConway/status/2120516902527062128/photo/1

#Dazodolibep #RCT in #SjD #CD40Li fusion protein no Fc 3 arms - 2 protocols ⬆️signs #ESSDAI>5. Entered >10 Other ⬆️#ESSPRI #Sjogren’s 1 or 2ndary (25%) 93%F -1.8 diff from PBO +results #ACRbest new Rx! #LB22 #ACR26 #ACRbest @RheumNow @ACRheum https://t.co/JJaDp0nCnM

Another potential treatment for treating Sjogren's: LB22: Ph3b efficacy & safety of Dazodalibep (DZP), CD40/CD40L inhbition VS PBO: - Wk 48; both DZP regimens improved ESDAI (diff v PBO -1.8 & -1.4) - tx effect early as wk 4 - Pt reported dryness also improved @RheumNow #ACR26 https://t.co/qa4dyr3e40

https://x.com/AkhilSoodMD/status/2120516142250983495/photo/1

Article

Falls Hide in Plain Sight in Rheumatic Disease

Jiha Lee, MD Nov 11, 2026

Katherine Wysham, MD, in the session “Rheumatology for Every Age” at ACR 2026 noted that falls are common in people with arthritis and underreported. A fall tends to start a cycle: lost confidence, less going out, reduced social participation, deconditioning, and then more falls and fractures.

Efgartigimod comes in with the first successful ph3 for IMNM (ALKIVIA trial) Nipocalimab ph2 missed primary but big numerical diff FcRN prob an obvious target for IMNM In a debilitating disease with minimal other options, it's a very good time ABSTLB24 ABST0905 #ACR26 @RheumNow https://t.co/c6RapsKKla

Wang et al. Retrospective cohort study. Hypogammaglobulinaemia in RA with RTX. The more you give the worse it gets (slowly and steadily). Threshold of 600 mg/dl appears to be tipping point in infection risk, HR 6.25, 95% CI 2.54-15.39; p< 0.001. @RheumNow #ACR26 Abstr#2931 https://t.co/JUtp51yug6

https://x.com/RichardPAConway/status/2120357345792340180/photo/1

Eye-opening abstract 1637 on leflunomide (LEF) in uveitis. Experience of single center uveitis population (n=147) 21% on LEF, always 2nd line or > (post MTX and/or ADA), most idiopathic/no SARD, ~ 1/2 of LEF Tx pts acheived remission or low uveitis activity. #ACR26 @RheumNow

Ab#2545 #ACR26 @RheumNow Post-exertional malaise (PEM) in Fibro study: PEM present in 3/4 of Long COVID pts, 1/4 SARD pts Fibro in 44% L-COVID, 21% SARD pts PEM more severe in L-COVID than SARD PEM severity signific assoc w/ worse phys fxn in both groups https://t.co/EaB9JRMC7I

In Vivo CAR-T in Lupus and Scleroderma: 14 Patients, no Lymphodepletion Three reports at ACR Convergence 2026 describe CD19 CAR-T cells generated inside the patient, with no apheresis and no ex vivo manufacturing step. None of the three used fludarabine and cyclophosphamide https://t.co/pYB2DjLqGc

Is it ok to re-analyze a #negative #RCT in #Raynaud’s Likely yes to learn how to study Ph3 or abandon drug Abst#2907 -neg RCT in #RP w #cilnidipine a marketed anti hypertensive Some ‘trends’ Studied to inform Future RCT on dose, outcome measures #ACR26 @RheumNow @ACRheum https://t.co/3AoiZ3juk4

SLE can permanently alter employment. In a cohort 1800pts followed a median 18 years, 84.3% of pts initially receiving disability benefits remained in that state. Renal, neuropsychiatric, endocrine and musculoskeletal damage predicted disability. @rheumnow #ACR26 Abstract #1266 https://t.co/9tzmAlJcx1